Proparacaine Hydrochloride Solution/ Drops
FDA Label NDC 85766-057

Full FDA labeling including Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Sportpharm Llc for the product Proparacaine Hydrochloride (NDC 85766-057). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding description, clinical pharmacology, indications and usage, contraindications, warnings, carcinogenesis, mutagenesis, impairment of fertility, pregnancy, nursing mothers, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Description

Proparacaine hydrochloride ophthalmic solution USP, 0.5% is a topical local anesthetic for ophthalmic use. The active ingredient is represented by the structural formula:

Established name:
Proparacaine Hydrochloride

Chemical name:
Benzoic acid, 3-amino-4-propoxy-,2-(diethylamino) ethyl ester, monohydrochloride

Chemical Structure (Image 01)

Chemical Structure (Image 01)

Molecular weight: 330.86

Each mL contains:

Active:proparacaine hydrochloride 5 mg (0.5%). Inactives:glycerin and purified water. The pH may be adjusted with hydrochloric acid and/or sodium hydroxide. Preservative:benzalkonium chloride (0.01%).

Clinical Pharmacology

Proparacaine hydrochloride ophthalmic solution is a rapidly-acting topical anesthetic, with induced anesthesia lasting approximately 10-20 minutes.

Indications And Usage

Proparacaine hydrochloride ophthalmic solution is indicated for procedures in which a topical ophthalmic anesthetic is indicated; corneal anesthesia of short duration, e.g. tonometry, gonioscopy, removal of corneal foreign bodies and for short corneal and conjunctival procedures.

Contraindications

Proparacaine hydrochloride ophthalmic solution is contraindicated in patients with known hypersensitivity to any of the ingredients of this preparation.

Warnings

NOT FOR INJECTION INTO THE EYE - FOR TOPICAL OPHTHALMIC USE ONLY

Prolonged use of a topical ocular anesthetic is not recommended. It may produce permanent corneal opacification with accompanying visual loss.

Carcinogenesis, Mutagenesis, Impairment Of Fertility

Long-term studies in animals have not been performed to evaluate carcinogenic potential, mutagenicity or possible impairment of fertility in males or females.

Pregnancy

Animal reproduction studies have not been conducted with proparacaine hydrochloride ophthalmic solution USP, 0.5%. It is also not known whether proparacaine hydrochloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Proparacaine hydrochloride should be administered to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when proparacaine hydrochloride is administered to a nursing woman.

Pediatric Use

Safety and effectiveness of proparacaine hydrochloride ophthalmic solution in pediatric patients have been established. Use of proparacaine hydrochloride is supported by evidence from adequate and well-controlled studies in adults and children over the age of twelve, and safety information in neonates and other pediatric patients.

Geriatric Use

No overall clinical differences in safety of effectiveness have been observed between the elderly and other adult patients.

Adverse Reactions

Occasional temporary stinging, burning and conjunctival redness may occur with the use of proparacaine. A rare, severe, immediate-type, apparently hyperallergic corneal reaction characterized by acute, intense and diffuse epithelial keratitis, a gray, ground glass appearance, sloughing of large areas of necrotic epithelium, corneal filaments and sometimes iritis with descemetitis has been reported.

Allergic contact dermatitis from proparacaine with drying and fissuring of the fingertips has been reported.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Dosage And Administration

Usual Dosage: Removal of foreign bodies and sutures, and for tonometry: 1 to 2 drops (in single instillations) in each eye before operating.

Short corneal and conjunctival procedures: 1 drop in each eye every 5 to 10 minutes for 5 to 7 doses.

NOTE:Proparacaine hydrochloride ophthalmic solution USP, 0.5% should be clear, colorless to faint yellow color. If the solution becomes darker, discard the solution.

FOR TOPICAL OPHTHALMIC USE ONLY

How Supplied

Proparacaine hydrochloride ophthalmic solution USP, 0.5% is supplied in a plastic bottle with a controlled drop tip and a white polypropylene cap in the following size:

NDC 85766-057-15 15 mL bottle (relabeled from NDC 24208-730-06)

Storage:

Refrigerate at 2°C to 8°C (36°F to 46°F). Protect from light. Keep tightly closed.

DO NOT USE IF IMPRINTED NECKBAND IS NOT INTACT.

Keep out of reach of children.

Distributed by:

Sportpharm

2237 N Commerce Parkway,

STE 1, Weston, Florida-33326

Relabeled by:

Enovachem PHARMACEUTICALS

Torrance, CA 90501

Principal Display Panel

Label (Label)

Label (Label)

* Please review the disclaimer below.